The success of Manchester Clinical Research Facility is based on the impact we make to the lives of our patients, their families, and our communities.
Read our Impact Case Studies below to find out how our clinical research is changing treatment, experiences, and improving outcomes for our patients and participants.
Therapies for people with Cystic Fibrosis (CF)
Manchester CRF has played a key role in clinical trials for some of the most recent and powerful therapies for CF for more than 10 years.
We were the lead site for the landmark triple therapy trials which has had life-changing impacts on the health of CF patients.
Advancing Treatment for Multiple Myeloma
Manchester CRF provides a dedicated early phase trials service for blood cancers, with patients referred from across the whole of the North of England.
We were the lead site for an early phase study of Elranatamab which, if approved, could benefit thousands of UK myeloma patients.
Improving Access to Respiratory Research
Manchester CRF successfully set up and delivered an early phase COPD clinical trial to bring research opportunities to communities in North Manchester.
By improving access to research, we are aiming to reduce health inequalities in the region.
New processes to help patients with rare conditions
Manchester CRF treated the first UK patient with a gene therapy for a rare genetic disorder.
With NIHR funding and collaborative working, we brought together expert teams to create a pathway for approving such trials, to meet regulatory standards.
Bringing people and cancer research together
Vocal, in partnership with Manchester CRF and Manchester BRC, Healthy Me, Healthy Communities, the LGBT Foundation and people affected by cancer, co-created Cancer & Us: Community Conversations.
ESCAPE: study of COVID-19 seroprevalence
Manchester CRF was asked to facilitate the fast-track opening and provide vital support to the Public Health England (PHE) ESCAPE (Enhanced Seroprevalence for COVID-19 Antibodies) study which aimed to better understand the spread of coronavirus by monitoring the development of and changes in antibodies linked to COVID-19 – the only NHS site to take part in the study.
Transforming the lives of people with cystic fibrosis: CF modulator therapies, from trial to patient.
Manchester CRF has been at the forefront of Cystic Fibrosis trials for almost a decade, and played a key role during a period that has seen rapid evolution of life-changing therapies, including trials of the most recent and most powerful triple combination therapies.
Strategic partnerships: AvroBio
Manchester Clinical Research Facility (MCRF), Manchester University NHS Foundation Trust (MFT) and the University of Manchester (UoM) have created a strategic partnership with AvroBio – a Massachusetts-based biotechnology company focused on delivering step-change cell and gene therapies targeting cancer and rare disease – to trial a first-in-person ex vivo gene therapy treatment using lentiviral vector-modified stem cells at the MCRF at Royal Manchester Children’s Hospital.
Addressing health inequalities through Manchester CRF infrastructure
Addressing health inequalities is a major strategic focus for Manchester Clinical Research Facility (MCRF), and public involvement in the design of clinical research can make a lasting impact in tacking these inequalities.